Piotr Rutkowski, MD, PhD, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland, describes a real-world study evaluating the efficacy of neoadjuvant targeted therapy for resectable stage IIIB-D or IV BRAF V600 mutation-positive melanoma. In the study, 29 patients received BRAF/MEK inhibitor treatment at a median time of 16 weeks before surgery. The results demonstrate that 8 patients achieved a complete pathologic response and a significantly improved progression free survival (PFS) was seen in patients with a pathological response of less than 10% viable cells in the tumor. This interview took place during the 10th World Congress of Melanoma in conjunction with the 17th EADO Congress Interactive Virtual Meeting.